Skip to main content

Apheresis | Plasmapheresis

Version: 15-06-2026 

What is the intervention?  

Blood consists of, among other things, red blood cells, white blood cells, platelets, and plasma. Plasma is the liquid part of the blood and contains, among other things, water, salts, proteins, antibodies, clotting factors, and inflammatory mediators. Apheresis is a medical technique in which the blood is temporarily diverted outside the body, and in which one or more components are removed or replaced. The remaining components, plus any replacement component, are returned to the patient. 

There are various forms of apheresis. In plasmapheresis, or therapeutic plasma exchange, plasma is removed and replaced by donor plasma or a replacement fluid, such as albumin. In immunoadsorption, primarily antibodies are bound to and removed from the plasma. In HELP apheresis, LDL cholesterol and fibrinogen, among others, are reduced. Other forms include leukapheresis, in which white blood cells are removed, and erythrocyte apheresis, in which red blood cells are removed or replaced. 

Apheresis is used within routine care for specific indications, such as certain autoimmune diseases, neurological disorders, hematological disorders, and severe lipid metabolism disorders. For post-COVID, plasmapheresis is also offered by some private clinics, sometimes under names such as HELP apheresis, INUSpheresis, or biopheresis. The techniques, targets, costs, and medical justification vary by provider. 

What is known about the mechanism of action of the intervention? 

The rationale for plasmapheresis in post-COVID is based on multiple hypotheses regarding possible biological mechanisms for persistent symptoms. In the literature, persistent inflammation, autoantibodies, immune complexes, endothelial activation, abnormal blood coagulation, fibrinogen or microclot formation, and impaired microcirculation are mentioned as possible factors in a subset of patients. 

In theory, plasmapheresis could work by removing various factors from the plasma, such as autoantibodies, cytokines, immune complexes, lipoproteins, or coagulation-related proteins. Immunoadsorption is more specifically aimed at removing immunoglobulins/antibodies. HELP apheresis primarily lowers LDL cholesterol, lipoprotein(a), and fibrinogen, and is being investigated in the context of post-COVID due to the hypothesis that fibrinogen, microclots, and increased viscosity may contribute to reduced blood flow and exercise intolerance. 

This mechanistic plausibility does not automatically mean that the treatment is clinically effective. Post-COVID, QVS, and other post-acute infectious syndromes are heterogeneous conditions. It is therefore possible that an intervention is only relevant for a subgroup with demonstrable immunological, coagulation, or inflammatory abnormalities. At present, it has not yet been sufficiently established which biomarkers reliably predict who benefits from plasmapheresis or immunoadsorption. 

What is known about the effect? 

Post-COVID

The clinical literature on plasmapheresis in post-COVID consists of small observational studies, mechanistic biomarker studies, a prospective cohort study on immunoadsorption in post-COVID ME/CFS, a trial protocol, and one randomized, double-blind, placebo-controlled phase II study on therapeutic plasma exchange. The results are inconclusive. 

In a small observational study in post-COVID patients, clinical improvement in symptoms such as chronic fatigue and brain fog, measured via validated subjective questionnaires, was reported after therapeutic apheresis. This was accompanied by a decrease in autoantibodies, lipids, fibrinogen, and inflammatory markers. This study provides biological leads but had significant limitations: no control group, small sample sizes, potential patient selection bias, and subjective outcomes. Consequently, no causal effect or association can be established.

A prospective cohort study in 20 patients who met the criteria for ME/CFS and had elevated β2 -adrenergic receptor autoantibodies investigated repeated immunoadsorption. Some of the patients showed improvement in functioning, fatigue, pain, or post-exertional malaise. However, a placebo-controlled comparison is lacking here as well, meaning that placebo effects, regression to the mean, and natural fluctuation of symptoms cannot be ruled out.

The strongest available study is a phase II, double-blind, placebo-controlled, randomized trial in which 50 patients with post-COVID received six sessions of therapeutic plasma exchange or sham treatment and were followed for 90 days. Safety was comparable between both groups, but no differences were found in functional status, symptoms, quality of life, neurocognitive complaints, or biochemical parameters. Therefore, this study does not support the conclusion that general therapeutic plasma exchange is effective for the broad post-COVID population. 

In summary, plasmapheresis in post-COVID is biologically plausible and has been experimentally investigated, but the clinical evidence is insufficient for routine use. There may be a subgroup with specific autoantibodies, inflammatory abnormalities, or coagulation-related features that may respond, but this subgroup has not yet been reliably defined. Treatment outside of a research setting therefore calls for great caution, especially when it is expensive and offered through private clinics. 

QOL

No clinical studies were found regarding plasmapheresis, HELP apheresis, or immunoadsorption in QVS. Although QVS, post-COVID, and ME/CVS may have partially overlapping symptoms, such as prolonged fatigue, exercise intolerance, and cognitive complaints, it has not been demonstrated that the underlying mechanisms are the same or that results from post-COVID or ME/CVS studies can be extrapolated to QVS. The effectiveness of apheresis in QVS has been insufficiently investigated. 

Chronic Q fever  

No studies were found that support plasmapheresis as a treatment for chronic Q fever. Chronic Q fever is a persistent infection with Coxiella burnetii requiring long-term antimicrobial treatment and specialist follow-up. Plasmapheresis does not eliminate intracellular bacterial infection and is not a substitute for the recommended treatment of chronic Q fever. The effectiveness of apheresis in chronic Q fever is unknown and not biologically substantiated as a causal treatment. 

Complaints after vaccination  

No controlled clinical studies were found regarding plasmapheresis or immunoadsorption for long-term symptoms following COVID-19 vaccination. Autoimmunity, inflammation, or coagulation processes are sometimes mentioned in hypothesis form, but there is no evidence that apheresis is effective or safe in this target group. The intervention has been insufficiently studied for symptoms following vaccination.

Accessibility, where applicable  

In the Netherlands, therapeutic apheresis is used within regular care for recognized medical indications, such as certain autoimmune diseases, neurological disorders, hematological disorders, and severe lipid metabolism disorders, and upon referral from a medical specialist. For post-COVID, QVS, chronic Q fever, or complaints following vaccination, plasmapheresis is not a standard treatment and is generally not reimbursed. 

Some private clinics abroad, and increasingly closer to the Netherlands, offer apheresis for post-COVID or similar complaints. Costs can be high and vary depending on the technique and number of sessions. Because the evidence for effectiveness is limited and contradictory, it is important that patients are well informed in advance about the uncertainty of effect, potential risks, financial costs, and the lack of broad reimbursement. 

Brief summary

Apheresis/plasmapheresis is a medical technique in which components are removed from the blood or plasma. For post-COVID, there is a biological rationale, but the clinical evidence is limited and contradictory. One controlled phase II study found no clinical benefit of therapeutic plasma exchange over sham treatment. Immunoadsorption and HELP apheresis remain experimental and possibly only relevant for subgroups that are as yet insufficiently defined. For QVS, chronic Q fever, and complaints following vaccination, evidence of effectiveness is lacking. 

Sources and scientific evidence 
  • Sanquin. Apheresis and therapeutic apheresis. Sanquin Blood Bank. 
  • Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher. 2023;38(2):77-278. 
  • Boedecker SC, et al. Immunoadsorption and plasma exchange – efficient treatment options for neurological autoimmune diseases. J Clin Apher. 2022;37(1):70-81. 
  • Stummvoll G, et al. Immunoadsorption in autoimmune diseases affecting the kidney. Semin Nephrol. 2017;37(5):478-487. 
  • Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133-146. 
  • Steenblock C, et al. Post-COVID and apheresis – where are we standing? Horm Metab Res. 2022;54(11):715-720. 
  • Fox T, Kelson M, Cuthbertson L, et al. Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition. Cochrane Database of Systematic Reviews. 2023. 
  • Preßler H, Machule ML, Kedor C, et al. IA-PACS-CFS: a double-blinded, randomized, sham-controlled, exploratory trial of immunoadsorption in patients with chronic fatigue syndrome including patients with post-acute COVID-19 CFS. Trials. 2024;25:172. 
  • Achleitner M, Steenblock C, Dänhardt J, et al. Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. Mol Psychiatry. 2023;28:2872-2877. 
  • Jaeger BR, et al. The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (HELP)-apheresis for patients with severe acute or chronic COVID-19. Front Cardiovasc Med. 2022;9. 
  • Tölle M, Freitag H, Antelmann M, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: efficacy of repeat immunoadsorption. J Clin Med. 2020;9(8):2443. 
  • Oesch-Régeni B, et al. The effect on quality of life of therapeutic plasmapheresis and intravenous immunoglobulins on a population of ME/CFS patients with elevated β-adrenergic and M3-muscarinic receptor antibodies – a pilot study. J Clin Med. 2025;14(11):3802. 
  • Stein E, Heindrich C, Wittke K, et al. Efficacy of repeated immunoadsorption in patients with post-COVID ME/CFS and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study. Lancet Regional Health – Europe. 2025;49:101161. 
  • España-Cueto S, et al. Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial. Nat Commun. 2025;16:1929. 
  • Rony RMIK, et al. Therapeutic plasma exchange: current and emerging applications. 2025.